Takeda Pharmaceuticals Company Ltd., founded in Japan in 1781, is focused on creating better health for people and a brighter future for the world. Takeda aims to discover and deliver life-transforming treatments in its core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with its partners, Takeda aims to improve the patient experience and advance a new frontier of treatment options through its dynamic and diverse pipeline. Takeda is committed to helping advance the science and clinical knowledge of inflammatory bowel disease and has developed strong relationships with key leaders within the field over its 35-year history in the gastroenterology therapeutic area. As a leading values-based, research and development-driven biopharmaceutical company, Takeda is guided by its commitment to patients, its people and the planet. Takeda’s employees in approximately 80 countries and regions are guided by their purpose and are grounded in the values that have defined the company for more than two centuries.
Role within INTERCEPT
As the industry lead on the INTERCEPT project, Takeda is providing in-kind support, contributing its expertise of personnel, samples and data from four key clinical studies in Crohn’s disease, as well as assisting collaboration efforts that unite public and private sector expertise and resources to more efficiently advance research in the space.
Takeda is proud to work together with IHI partners on the INTERCEPT project aiming to realise their ultimate, shared goal – to shift Crohn’s disease from an incurable condition where current treatment options focus on disease management, to one that could be effectively managed and possibly prevented.
Main contacts
Dr. Pratik Panchal
Medical Director & Head of Inflammatory Bowel Disease Product Science, Gastrointestinal and Inflammation Therapeutic Area
Dr. Marcelo Freire de Oliveira
Vice President, Global Medical Affairs, Gastrointestinal Therapeutic Area Head Ms. Kari Thostenson
Dr. Christian Agboton
Global Medical Unit Head, Entyvio & New Programs IBD, Global Medical Affairs GI
Ms. Kari Thostenson
Director, Business Operations, Gastrointestinal and Inflammation Therapeutic Area